Literature DB >> 17350045

The emotional and psychological impact of multiple sclerosis relapses.

Rosalind Kalb1.   

Abstract

Acute relapses of multiple sclerosis (MS) are experienced as crises that disrupt the status quo for individuals with MS and their families. These unpredictable--and always unexpected--events elicit strong reactions, including grief, anxiety, anger, and guilt, as people struggle to understand why they occur. Although early relapses are a signal for most MS specialists to recommend treatment with one of the approved disease-modifying therapies, the remissions that follow contribute to patient and family denial about the realities of the disease, making it difficult for patients to begin and to adhere to ongoing treatment. Each ensuing attack confronts this denial, forcing patients and families to acknowledge the MS diagnosis and begin adapting to the demands of the illness in their daily lives. This paper discusses the meaning attributed by individuals and families to relapses leading to the MS diagnosis and the recommendation for disease-modifying therapy, the adjustments that are made by patients and their families to residual deficits following acute episodes, and suggestions for clinicians on how they might facilitate the adjustment process.

Entities:  

Mesh:

Year:  2007        PMID: 17350045     DOI: 10.1016/j.jns.2007.01.061

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

1.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

2.  Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience.

Authors:  Nunzia Rainone; Alessandro Chiodi; Roberta Lanzillo; Valeria Magri; Anna Napolitano; Vincenzo Brescia Morra; Paolo Valerio; Maria Francesca Freda
Journal:  Qual Life Res       Date:  2016-12-07       Impact factor: 4.147

3.  Burden of a multiple sclerosis relapse: the patient's perspective.

Authors:  Merrikay Oleen-Burkey; Jane Castelli-Haley; Maureen J Lage; Kenneth P Johnson
Journal:  Patient       Date:  2012       Impact factor: 3.883

4.  The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis.

Authors:  Brian C Healy; Irene R Degano; Ana Schreck; David Rintell; Howard Weiner; Tanuja Chitnis; Bonnie I Glanz
Journal:  Qual Life Res       Date:  2012-01-12       Impact factor: 4.147

5.  Validation of a new quality of life scale related to multiple sclerosis and relapses.

Authors:  Antoine Baroin; Gilles Chopard; Gaye Siliman; Clément Michoudet; Aurore Vivot; Chrystelle Vidal; Hassna Mokadym; Annick Lavier; Eric Berger; Lucien Rumbach; Nathalie Rude
Journal:  Qual Life Res       Date:  2012-12-18       Impact factor: 4.147

6.  Examining the Relationship Between Family Caregivers' Emotional States and Ability to Empathize with Patients with Multiple Sclerosis: A Pilot Study.

Authors:  Sepideh Pooyania; Michelle Lobchuk; Wanda Chernomas; Ruth Ann Marrie
Journal:  Int J MS Care       Date:  2016 May-Jun

7.  The Mental Health Needs of Individuals Living With Multiple Sclerosis: Implications for Occupational Therapy Practice and Research.

Authors:  Arcenio Mesa; Kathryn Hoehn Anderson; Sally Askey-Jones; Richard Gray; Eli Silber
Journal:  Mental Health Spec Interest Sect Q       Date:  2012

Review 8.  The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.

Authors:  Ting Yang; Xin Tian; Chao-Yang Chen; Ling-Yun Ma; Shuang Zhou; Min Li; Ye Wu; Ying Zhou; Yi-Min Cui
Journal:  Br J Clin Pharmacol       Date:  2020-02-08       Impact factor: 4.335

9.  Qualitative study identifies life shifts and stress coping strategies in people with multiple sclerosis.

Authors:  Heidemarie Lex; Pollie Price; Lauren Clark
Journal:  Sci Rep       Date:  2022-04-20       Impact factor: 4.996

10.  Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

Authors:  Paul W O'Connor; Fred D Lublin; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Mark S Freedman; Tomas P Olsson; Aaron E Miller; Catherine Dive-Pouletty; Gaëlle Bégo-Le-Bagousse; Ludwig Kappos
Journal:  J Neurol       Date:  2013-07-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.